Stockscreener 앱 받기
12.19
0.08%
-0.010
시간 외 거래:
12.14
-0.05
-0.41%
전일 마감가:
$12.20
열려 있는:
$12.23
하루 거래량:
31,048
Relative Volume:
0.37
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.09%
1개월 성능:
-2.17%
6개월 성능:
+21.78%
1년 성능:
+148.27%
1일 변동 폭
$12.13
$12.60
1주일 범위
$10.66
$12.60
52주 변동 폭
$4.74
$14.25
Direxion Daily Pharmaceutical Medical Bull 3 X Etf Stock (PILL) Company Profile
명칭
Direxion Daily Pharmaceutical Medical Bull 3 X Etf
전화
-
주소
-
Compare PILL vs VTI, SPY, IVV, VB, QQQ
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PILL
Direxion Daily Pharmaceutical Medical Bull 3 X Etf
|
12.19 | 0 | 0 | 0 | 0 | 0.00 |
VTI
Vanguard Total Stock Market Etf
|
366.79 | 417.53B | 0 | 0 | 0 | 0.00 |
SPY
Spdr S P 500 Etf Trust
|
745.64 | 372.57B | 0 | 0 | 0 | 0.00 |
IVV
Ishares Core S P 500 Etf
|
749.14 | 253.41B | 0 | 0 | 0 | 0.00 |
VB
Vanguard Small Cap Etf
|
289.09 | 160.59B | 0 | 0 | 0 | 0.00 |
QQQ
Invesco Qqq Trust Series 1
|
717.54 | 124.43B | 0 | 0 | 0 | 0.00 |
Direxion Daily Pharmaceutical Medical Bull 3 X Etf 주식(PILL)의 최신 뉴스
Liquidity Mapping Around (PILL) Price Events - Stock Traders Daily
Direxion Daily Pharmaceutical & Medical Bull 3x Etf Live Share Price (PILL.US) - London South East
Inverse and Leveraged ETFs: How Do They Work? - Britannica
Why (PILL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Top Performing Leveraged/Inverse ETFs: 04/26/2026 - etftrends.com
LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout - 24/7 Wall St.
Direxion Daily Pharmaceutical & Medical Bull 3X Shares declares quarterly distribution of $0.0327 - MSN
ARCA Stocks: Research Stocks from ARCA - GuruFocus
Leveraged ETFs Explained: 3 Picks for Active Traders Who Want Speed - 24/7 Wall St.
Direxion Daily Pharmaceutical & Medical Bull 3X Shares declares quarterly distribution of $0.0109 - msn.com
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here’s How to Position Now - AOL.com
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now - 24/7 Wall St.
Understanding Momentum Shifts in (PILL) - Stock Traders Daily
Volatility Meets Earnings Season – Q1 2026 - Direxion
If Technology Stocks Are Ready To Rally, The Leveraged TECL ETF Will Magnify Gains - Seeking Alpha
Avoiding Lag: Real-Time Signals in (PILL) Movement - Stock Traders Daily
CURE: Pullback In Healthcare Stocks Presents A Buying Opportunity (NYSEARCA:CURE) - Seeking Alpha
Stock List: Research Stocks from Around the World - gurufocus.com
Discipline and Rules-Based Execution in PILL Response - Stock Traders Daily
Direxion Daily Healthcare Bull 3X Shares declares quarterly distribution of $0.2912 - MSN
Osteoarthritis Pipeline Witnesses Strong Expansion with 100+ Companies Advancing 110+ Innovative Therapies | DelveInsight - Barchart
Direxion Daily Healthcare Bull 3X Shares declares quarterly distribution of $0.3101 - MSN
Behavioral Patterns of PILL and Institutional Flows - Stock Traders Daily
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart
SOXL Semiconductor Bull 3X ETF: Watch Nothing But Price Action (Technical Analysis) - Seeking Alpha
Medical Biomimetics Market Forecast to Reach USD 85.94 Billion by 2031 Driven by Tissue Engineering Demand, Regenerative Medicine Adoption, and Expanding Clinical Applications - Barchart.com
How Is West Pharmaceutical's Stock Performance Compared to Other Healthcare Stocks? - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart.com
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight | Kartos Therapeutics, AOP Orphan Pharmaceuticals - Barchart
Dr. Ranjan Rajbanshi Scholarship for Medical Students Announces National Essay Competition for Aspiring Healthcare Professionals - Barchart.com
(PILL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies - Barchart.com
Pharmaceutical Drug Delivery Market Projected to Reach $2,546.0 Billion by 2029 with Advancements in Targeted Therapies - Barchart.com
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Barchart.com
Paroxysmal Nocturnal Hemoglobinuria Market: Expanding Revenue Landscape to 2034 – DelveInsight | Alexion Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, AKARI Therapeutics, AstraZeneca - Barchart.com
Multiple Myeloma Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Barchart.com
Regional Bank Melt-Up: Is This 3X Leveraged Play the Ultimate High-Reward Bet? - AOL.com
How (PILL) Movements Inform Risk Allocation Models - Stock Traders Daily
Hypertension Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - Barchart.com
How to Invest in Direxion Daily Robotics, AI & Automation Index Bull 2X Shares (UBOT) - The Motley Fool
Student-Led Nonprofit Empathy in Medicine Initiative Launches National Chapter for High School and College Students - Barchart.com
North America Biomarkers Market to Reach $42.25 Billion by 2030, Driven by Precision Medicine and Safety Biomarker Adoption - Barchart.com
Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value - Barchart.com
XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500 - AOL.com
XLRE Trails the S&P 500 by 5% Despite Lower Interest Rates That Were Supposed To Help - AOL.com
Trading Systems Reacting to (PILL) Volatility - Stock Traders Daily
EDC: A Highly Leveraged Play On The Daily Movements Of Emerging Markets (NYSEARCA:EDC) - Seeking Alpha
6 Best Defense ETFs to Watch in 2026 - The Motley Fool
5 Small-cap Biotech ETFs to Watch - Investing News Network
Direxion Daily Pharmaceutical Medical Bull 3 X Etf (PILL) 재무 분석
Direxion Daily Pharmaceutical Medical Bull 3 X Etf (PILL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.90%
0.20%
자본화:
|
볼륨(24시간):